Literature DB >> 442877

Further progress with oncolysis due to apathogenic clostridia.

D Gericke, F Dietzel, W König, I Rüster, L Schumacher.   

Abstract

Cl. onc. apathogenic for human beings and small animals is not able to cure tumor-bearing hosts. Combined treatments with local X-irradiation and local HFH have decreased the death rate of Harding-Passey-Melanoma-bearing mice. A cure rate of ca. 20% has resulted for the first time in such experiments. The survival time has increased significantly, however relapses occured on the sites of transplantation which finally killed the animals. Therefore it was tried to repeat the threefold-combined treatment. The animals with a relapse tolerated such a second and third series well. After the second series of treatment some animals became free of relapse and some after the third series. That means, if repeating treatment with local HFH, local X-irradiation, and i.v. spore-application of Cl. onc., it is possible to cure the Harding-Passey-Melanoma of the mouse at a high percentage.

Entities:  

Mesh:

Year:  1979        PMID: 442877

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Orig A        ISSN: 0300-9688


  3 in total

Review 1.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 2.  Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities.

Authors:  Mansour Sedighi; Abed Zahedi Bialvaei; Michael R Hamblin; Elnaz Ohadi; Arezoo Asadi; Masoumeh Halajzadeh; Vahid Lohrasbi; Nima Mohammadzadeh; Taghi Amiriani; Marcela Krutova; Abolfazl Amini; Ebrahim Kouhsari
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

3.  Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.

Authors:  J Theys; O Pennington; L Dubois; G Anlezark; T Vaughan; A Mengesha; W Landuyt; J Anné; P J Burke; P Dûrre; B G Wouters; N P Minton; P Lambin
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.